Severe per

Severe perinatal outcomes more common in women with moderate-to-severe COVID-19 during Delta period

A study published in Nature Communications showed that severe perinatal outcomes were more common in women with moderate-to-severe COVID-19 during the Delta-dominant period and among unvaccinated women. “The risk of preterm birth was increased for babies born to women with moderate-to-severe infection across all periods,” reported Hilde Marie Engjom, University of Oxford, Oxford, United Kingdom, and colleagues. “Omicron was considered to be a variant with lower risk of adverse perinatal outcomes, yet we observed a 3-fold increase in risk of birth prior to 34 weeks’ gestation for women with ...

Adults With Congenital Heart Disease Face Higher Risk of Arrhythmias

A significant percentage of adults with congenital heart disease develop arrhythmias, which has a significant impact on healthcare usage and outcomes, according to a study published in the Journal of the American Heart Association. “Our findings h...

Acute Cardiac Events Common in Older Adults Hospitalised With RSV

Acute cardiac events are prevalent among older adults hospitalised with laboratory-confirmed respiratory syncytial virus (RSV) infection, according to a study published in JAMA Internal Medicine. “Emerging evidence raises concerns about acute card...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Late Break
8:18

Late Breaking Clinical Trial on ACC

Presenter: Athena Poppas
Cardiology
ACC 2024
Late-Break
8:17

Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise

Presenter: Andrew M. Kates
Cardiology
ACC 2024
Featured C
9:36

Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements

Presenter: George Dangas
Cardiology
ACC 2024
Semaglutid
12:05

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials

Presenter: Mikhail Kosiborod
Cardiology
ACC 2024
Late Break
8:56

Late Breaking Clinical Trial on interventional cardiology

Presenter: Douglas E. Drachman
Cardiology
ACC 2024
Joint Amer
8:57

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV

Presenter: Kathryn L. Berlacher
Cardiology
ACC 2024
Late-Break
7:56

Late-Breaking Clinical Trials V

Presenter: Edward T. A. Fry
Cardiology
ACC 2024
PROACT: Do
4:30

PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma?

Presenter: David Austin
Cardiology
ACC 2024
Lerodalcib
21:56

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients

Presenter: Eric Quinton Klug
Cardiology
ACC 2024
Outcomes A
7:49

Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial

Presenter: Steven E. Nissen
Cardiology
ACC 2024
EMPACT-MI:
8:47

EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death

Presenter: Javed Butler
Cardiology
ACC 2024
ULTIMATE-D
6:50

ULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI

Presenter: Gregg Stone
Cardiology
ACC 2024
Study Link
2:59

Study Links E-Cigarette Use with Higher Risk of Heart Failure

Presenter: Yakubu Bene-Alhasan
Cardiology
ACC 2024
Percutaneo
5:47

Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock

Presenter: Robert Roswell
Cardiology
ACC 2024
Joint Amer
9:47

Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials

Presenter: B. Hadley Wilson
Cardiology
ACC 2024
Follicular
12:06

Follicular Lymphoma highlights of the ASH 2023 Congress

Presenter: Carla Casulo
Oncology : Hematology
ASH 2023
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology
Once-weekl
1:17

Once-weekly semaglutide in people with HFpEF and obesity

Presenter: Mikhail Kosiborod
Cardiology
Should ABP
1:31

Should ABPM parameters have a role in clinical practice?

Presenter: Paolo Palatini
Cardiology